Meeting
2023 ASCO Annual Meeting
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
Authors
Elisabeth Carola
GHPSO, Senlis, France
Elisabeth Carola , Marina Pulido , Claire Falandry , Elena Paillaud , Philippe Caillet , Louis Tassy , Michael Bringuier , Godelieve Rochette de Lempdes , Jessica Grosjean , William Mina , Olivier Guillem , Nicolas Jovenin , Isabelle Desmoulins , Fanny Bouteiller , Dounia Bettache , Nada Rifi , Etienne Brain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1018)
DOI
10.1200/JCO.2023.41.16_suppl.1018
Abstract #
1018
Poster Bd #
239
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
First Author: Seock-Ah Im